Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Dec 15;3(10):e958937. doi: 10.4161/21624011.2014.958937

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Author(s). Published with license by Taylor & Francis Group, LLC

© Tuuli Ranki, Timo Joensuu, Elke Jäger, Julia Karbach, Claudia Wahle, Kalevi Kairemo, Tuomo Alanko, Kaarina Partanen, Riku Turkki, Nina Linder, Johan Lundin, Ari Ristimäki, Matti Kankainen, Akseli Hemminki, Charlotta Backman, Kasper Dienel, Mikael von Euler, Elina Haavisto, Tiina Hakonen, Juuso Juhila, Magnus Jaderberg, Petri Priha, Lotta Vassilev, Antti Vuolanto, and Sari Pesonen

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 2. — IFNγ enzyme linked immunospot assay (ELISPOT) for MAGE-A3-specific (p271–279 FLWGPRALV) CD8⁺ T-cells was performed. Purified CD8⁺ were pre-sensitized with peptide-pulsed, irradiated autologous PBMCs depleted of CD4⁺ and CD8⁺ T-cells and tested on day 10 by IFNγ ELISPOT assay for recognition of autologous antigen-presenting cells. The number of cytokine-producing antigen-specific T-cells was evaluated using AID EliSpot Reader Classic ELR 07 (Autoimmun Diagnostika GmbH, Strassberg, Germany). Cells without peptide stimulation (−) and with MAGE-A3 stimulation (+) are shown from samples obtained at baseline (A), 1–4 weeks after treatment initiation (B) and 20–24 weeks after treatment initiation (C).